Literature DB >> 19669302

Should chronic HBV infected patients with normal ALT treated: debate.

Shiv Kumar Sarin1, Manoj Kumar.   

Abstract

Alanine aminotransferase (ALT) levels have traditionally been used for treatment decisions in chronic hepatitis B virus (CHBV) infected patients. But recent data have raised doubts on this wisdom, as a significant proportion of CHBV infected patients with normal ALT have high HBVDNA levels and significant liver injury at presentation especially in areas of intermediate to high endemicity. A normal ALT value only identifies patients less likely to respond to current treatments, rather than patients who are not in need of the treatment. Patients with CHBV infection with normal ALT should be considered for treatment based on the HBV DNA levels and histological injury.

Entities:  

Year:  2008        PMID: 19669302      PMCID: PMC2716854          DOI: 10.1007/s12072-008-9065-2

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  38 in total

Review 1.  Hepatitis B e antigen-negative chronic hepatitis B.

Authors:  S J Hadziyannis; D Vassilopoulos
Journal:  Hepatology       Date:  2001-10       Impact factor: 17.425

2.  Carriers of hepatitis B antigen: an epidemiologic and histologic study.

Authors:  G Ricci; C De Bac; F Caramia
Journal:  J Infect Dis       Date:  1973-07       Impact factor: 5.226

3.  One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels.

Authors:  Danny Ka-Ho Wong; Man-Fung Yuen; Vincent Wing-Shun Ngai; James Fung; Ching-Lung Lai
Journal:  Antivir Ther       Date:  2006

4.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

Authors:  Stephanos J Hadziyannis; Nicolaos C Tassopoulos; E Jenny Heathcote; Ting-Tsung Chang; George Kitis; Mario Rizzetto; Patrick Marcellin; Seng Gee Lim; Zachary Goodman; Jia Ma; Sarah Arterburn; Shelly Xiong; Graeme Currie; Carol L Brosgart
Journal:  N Engl J Med       Date:  2005-06-30       Impact factor: 91.245

5.  Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications.

Authors:  M-F Yuen; H-J Yuan; D K-H Wong; J C-H Yuen; W-M Wong; A O-O Chan; B C-Y Wong; K-C Lai; C-L Lai
Journal:  Gut       Date:  2005-05-04       Impact factor: 23.059

6.  Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study.

Authors:  Maurizia Rossana Brunetto; Filippo Oliveri; Barbara Coco; Gioacchino Leandro; Piero Colombatto; Juliana Monti Gorin; Ferruccio Bonino
Journal:  J Hepatol       Date:  2002-02       Impact factor: 25.083

Review 7.  A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update.

Authors:  Emmet B Keeffe; Douglas T Dieterich; Steven-Huy B Han; Ira M Jacobson; Paul Martin; Eugene R Schiff; Hillel Tobias; Teresa L Wright
Journal:  Clin Gastroenterol Hepatol       Date:  2006-07-14       Impact factor: 11.382

8.  Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years.

Authors:  Mauro Manno; Calogero Cammà; Filippo Schepis; Fabio Bassi; Roberta Gelmini; Francesco Giannini; Francesca Miselli; Antonella Grottola; Ilva Ferretti; Chiara Vecchi; Marisa De Palma; Erica Villa
Journal:  Gastroenterology       Date:  2004-09       Impact factor: 22.682

9.  Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study.

Authors:  Hyeon Chang Kim; Chung Mo Nam; Sun Ha Jee; Kwang Hyub Han; Dae Kyu Oh; Il Suh
Journal:  BMJ       Date:  2004-03-17

10.  Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis.

Authors:  A D Enriquez; M S Campbell; K R Reddy
Journal:  Aliment Pharmacol Ther       Date:  2007-08-01       Impact factor: 8.171

View more
  2 in total

1.  Alanine aminotransferase is more sensitive to the decrease in hepatitis B virus-DNA load than other liver markers in chronic hepatitis B patients.

Authors:  Hua-Bin Wang; Qiong-Yu Wang; Qing Yuan; Xiao-Yun Shan; Guan-Hua Fu
Journal:  J Clin Lab Anal       Date:  2017-01-23       Impact factor: 2.352

2.  Long-term hepatitis B virus infection of rhesus macaques requires suppression of host immunity.

Authors:  Sreya Biswas; Lauren N Rust; Jochen M Wettengel; Sofiya Yusova; Miranda Fischer; Julien N Carson; Josie Johnson; Lei Wei; Trason Thode; Mohan R Kaadige; Sunil Sharma; Majd Agbaria; Benjamin N Bimber; Thomas Tu; Ulrike Protzer; Alexander Ploss; Jeremy V Smedley; Gershon Golomb; Jonah B Sacha; Benjamin J Burwitz
Journal:  Nat Commun       Date:  2022-05-30       Impact factor: 17.694

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.